Table 3 Number of adverse events over the study period
Omega 3 (n = 19) | Control (n = 21) | Total (n = 40) | |
|---|---|---|---|
Cardiac disorders | 5 | 1 | 6 |
Ear and labyrinth | 0 | 1 | 1 |
Eye disorders | 0 | 1 | 1 |
Gastrointestinal | 17 | 12 | 29 |
General disorders | 7 | 7 | 14 |
Infections and infestations | 5 | 8 | 13 |
Injury, poisoning and procedural complications | 4 | 1 | 5 |
Investigations | 1 | 0 | 1 |
Musculoskeletal | 18 | 12 | 31 |
Neoplasm | 0 | 1 | 1 |
Nervous system disorders | 2 | 5 | 7 |
Psychiatric disorders | 1 | 2 | 3 |
Renal and urinary | 0 | 1 | 1 |
Respiratory | 3 | 6 | 9 |
Skin and subcutaneous | 1 | 1 | 2 |
Vascular disorders | 1 | 1 | 2 |
Total | 65 | 61 | 126 |